X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-continues-momentum-in-ongoing-potentially-pivotal-global-trial-evaluating-berubicin-for-the-treatment-of-gbm-with-first-patient-enrolled-in-switzerland-301766407.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-first-patient-enrolled-in-spain-in-ongoing-potentially-pivotal-global-trial-evaluating-berubicin-for-the-treatment-of-gbm-301740570.html
https://www.clinicaltrialsarena.com/news/cns-brain-cancer-trial/
https://www.clinicaltrialsarena.com/news/cns-activates-european-sites/
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-receives-approval-from-us-fda-for-protocol-amendment-to-ongoing-potentially-pivotal-global-trial-evaluating-berubicin-for-the-treatment-of-gbm-301573601.html
https://www.clinicaltrialsarena.com/news/cns-berubicin-glioblastoma-multiforme/
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-receives-approval-from-france-ethics-committee-and-competent-authority-for-potentially-pivotal-study-of-berubicin-for-the-treatment-of-glioblastoma-multiforme-gbm-301518789.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-continues-to-execute-on-corporate-clinical-and-regulatory-strategies-to-drive-berubicin-towards-commercialization-for-the-treatment-of-gbm-301324229.html
https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-cns-pharmaceuticals-for-berubicin-for-the-treatment-of-recurrent-glioblastoma-multiforme-301321481.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-call-to-discuss-fda-ind-approval-and-phase-2-trial-for-berubicin-301195577.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-adaptive-trial-design-for-berubicin-phase-2-clinical-trial-to-be-submitted-for-fda-review-301168491.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-completes-manufacturing-of-berubicin-for-phase-2-clinical-trial-301162523.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-completes-manufacturing-of-berubicin-for-phase-2-clinical-trial-301162523.html#:~:text=By%20the%20end%20of%202020,pediatric%20GBM%20patients%20in%20Poland.
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-completes-us-manufacturing-of-berubicin-for-phase-2-clinical-trial-301155358.html
https://www.contractpharma.com/contents/view_breaking-news/2020-10-20/cns-pharmaceuticals-completes-us-manufacturing-of-berubicin/
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-achieves-critical-manufacturing-milestone-301143626.html
https://www.contractpharma.com/contents/view_breaking-news/2020-10-01/nck-as-receives-coa-for-berubicin-api/
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-and-image-analysis-group-partner-to-further-the-development-of-berubicin-301137257.html
https://www.contractpharma.com/contents/view_breaking-news/2020-09-04/cns-achieves-key-milestones-in-berubicin-dual-track-mfg-strategy/
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-completes-drug-product-manufacturing-strategy-for-berubicin-301093804.html
https://www.prnewswire.com/news-releases/cns-announces-nasdaq-trading-halt-pending-receipt-of-additional-information-301060580.html
https://www.prnewswire.com/news-releases/cns-provides-additional-comments-regarding-trading-halt-301056441.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-and-wpd-pharmaceuticals-identify-leading-polish-medical-institutions-for-berubicin-phase-2-clinical-trial-301050028.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-filing-of-fda-orphan-drug-designation-for-brain-cancer-drug-berubicin-301045756.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-shareholder-webinar-to-discuss-collaboration-with-wpd-pharmaceuticals-for-developing-coronavirus-drug-candidates-the-significance-of-wp1244-and-an-update-on-the-cancer-free-survivor-treated-with-ber-301040816.html
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-contract-with-international-gmp-manufacturer-for-production-of-berubicin-300986285.html
https://www.prnewswire.com/news-releases/cns-berubicin-awarded-5-8-million-non-dilutive-grant-from-eupolish-national-center-through-its-development-partner-300972730.html
Market Place
Share 
